Moringa Acquisition Warrant Stock Price, News & Analysis
MACAW
NASDAQ
Company Description
Moringa Acquisition Corp (Nasdaq: MACA) is a blank check company focused on effecting a business combination with Israel-related technology companies. Recently, Moringa announced a merger with Silexion Ltd., an oncology-focused biotechnology company, with promising products like Loder™ showing significant efficacy in clinical trials. The proposed merger aims to provide shareholders the opportunity to participate in Silexion's innovative platform as a publicly listed Nasdaq company.
Stock Performance
$—
0.00%
0.00
Last updated:
607.55 %
Performance 1 year
$0.0
Market Cap
0.0
Shares outstanding
Latest News
SEC Filings
No SEC filings available for Moringa Acquisition Warrant.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the current stock price of Moringa Acquisition Warrant (MACAW)?
The current stock price of Moringa Acquisition Warrant (MACAW) is $0.12 as of February 7, 2025.
What is Moringa Acquisition Corp?
Moringa Acquisition Corp (Nasdaq: MACA) is a blank check company focusing on merging with Israel-related technology companies.
Who is Silexion Ltd?
Silexion Ltd. is a clinical-stage biotechnology company specializing in oncology treatments, with innovative products like Loder™.
What is the purpose of the merger between Moringa and Silexion?
The merger aims to make Silexion a publicly listed Nasdaq company, offering shareholders the potential to participate in Silexion's advanced platform.
What are the key transaction terms of the business combination?
Moringa will issue 6.25 million shares to Silexion's equity holders, and the combined board will have seven members.
When is the expected closing date of the merger?
The merger is anticipated to close in the third quarter of 2024, subject to shareholder and Nasdaq approval.
What are the main products developed by Silexion?
Silexion focuses on innovative oncology treatments, with products like Loder™ and SIL-204B.
Who are the legal counsels for Moringa and Silexion?
Meitar | Law Offices and Greenberg Traurig represent Moringa, while Herzog Fox & Neeman serve as legal counsels for Silexion.
Where can shareholders find more information about the proposed business combination?
Shareholders can access relevant documents on the SEC's website or Moringa's Investor Relations section.
What are the risks associated with the proposed transaction?
Risks include the timing of completion, market value impact, regulatory approvals, and business disruption.
Who are the participants in the solicitation for the business combination?
Directors, officers, and employees of Moringa and Silexion may be involved in soliciting proxies from Moringa's shareholders.